ESTRO 35 2016 _____________________________________________________________________________________________________ perform the selection procedure for a set of patients. Subsequently, the choices are discussed in the group of observers and a set of selection rules is composed. In this lecture we will discuss the plan selection strategy for rectum cancer and its introduction in the clinic.
PV-0425 EEF2K promotes progression and radioresistance of esophageal squamous cell carcinoma H.C. Zhu 1 The First Affiliated Hospital of Nanjing Medical University, Radiation Oncology, Nanjing, China 1 , X. Yang 1 , X.L. Ge 1 , J.Y. Chen 1 , H.M. Song 1 , J. Liu 1 , Z.L. Pei 1 , M.Q. Chen 1 , X.C. Sun 1 Purpose or Objective: We investigated the effects of eukaryotic elongation factor 2 kinase (EEF2K) in esophageal squamous cell carcinoma (ESCC) and its role in radiosensivity.
Material and Methods:
We used quantitative real-time polymerase chain reaction and immunohistochemistry analyses to compare expression of EEF2K between paired ESCC samples and nontumor esophageal tissues. Lentivirus was used to overexpress and knockdown of EEF2K gene and stable transmitted cell line of ECA109 and TE13 were made. In vitro cell counting kit 8 and clone formation assay were used to detect cell viability and proliferation. Wound-healing migration assay, transwell invasion assay three-dimensional culture and tube formation assay were used to investigate invasion, metastasis and angiogenesis of ESCC. Radioresponse was primary examined by clone formation assay after exposure of 0, 2, 4, 6, 8 Gy X-ray by a medical accelerator of different stable cell lines. Then apoptosis, cell-cycle arrest, and γ-H2AX expression were examined in 0 Gy and 8 Gy in the overexpressed and knockdown ESCC cell line by flow cytometer and immunoflourence. Gene-chips and western blot were used to investigate molecular mechanism. In vivo experiments of xenografts were used to confirm the results.
Results: Levels of eEF2K were increased 52.17% of ESCC samples compared with matched nontumor tissues, as well as ESCC cell lines. Increased levels of eEF2K were associated with ESCC survival times of patients (P<0.05). eEF2K expression correlated between tumor size and TNM stage in primary ESCC during clinicopathological feature analysis (P<0.05). EEF2K promotes ESCC proliferation and tumorgeneity in vitro and in vivo. Improved invasion, metastasis and angiogenesis were also seen in EEF2K overexpressed cells compared with control in TE13 and ECA109 cell lines. An improved radioresponse was detected in eEF2K knockdown cells which could also be induced by NH125, an eEF2K inhibitor. Affymetrix GeneChip were used in EEF2K overexpressed ECA109 and control cells in normal conditions and 8 Gy of irradiation and autophagy pathways were detected by bioinformatic analysis. Improved protein expression of Atg5, mTOR, LC3, and TP53 were confirmed by western blot. In xengraft radiosensivity experiments, an enhancement factor of 1.78 was seen in ECA109 bearing nude mouse by NH125, along with a reduction of tumor doubling time. Immunohistochemistry and immunofluorescence of tumor tissue confirmed the molecular mechanism of autophagy pathway.
Conclusion: EEF2K is overexpressed in ESCC and associated with progression and shorter survival times of patients. Decreased expression of EEF2K correlated with a reduction of malignancy in biological behavior and an improvement of radioresistance in ESCC, which may be mediated by autophagy signaling pathway. Targeting EEF2K may be a potential therapeutic approach of ESCC in the future. pathways which control the cell motility and proliferation, is produced by phosphatidylinositol 4-kinase (PI4K). Thus, an inhibition of PI4K could inactivate these two PI4P dependent pathways simultaneously. In this study, we tried to identify that which isotype of PI4K may affect a radiosensitivity using RNA interference (RNAi) and also to investigate anti-hepatitis C viral (HCV) agents which are known to inhibit PI4K activity, could be repositioned as a radiosensitizer in human breast cancer, glioblastoma and hepatoma models.
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Material and Methods:
A panel of human cancer cell lines including U251 malignant glioma cells, BT474 breast cancer cells, and HepG2 hepatocellular carcinoma cells were used. RNAi was used to specific inhibition of each isotype of PI4K and clonogenic assay was performed to assess the radiosensitizing effect of each isotype. To select an anti-HCV agent for pharmacologic inhibition of PI4K, IC50s of nine commercial antiviral agents were determined. Specific inhibitory effect on PI4K isotype was determined by in vitro kinase assay. Radiosensitizing effect of the selected anti-HCV agents were tested by clonogenic assay in vitro and tumor xenograft model in vivo, respectively. Immunoblotting, immunocytochemistry, and invasion/migration assay were performed to identify the mechanism of radiosensitization.
Results: First, we identified that specific inhibition of PI4K IIIα using RNAi increased radiosensitivity in the human cancer cell lines we tested. In contrast, inhibition of other isotypes did not affect a radiosensitivity of these cancer cell lines. Next, in vitro kinase assays showed, simeprevir, a selected anti-HCV agent via IC50 assay, inhibited activity of PI4K IIIα in a dose-response manner. Pretreatment of simeprevir induced discernible downregulation of p-PKC and p-Akt and also increased clonogenic survival of U251, BT474, and HepG2 cells in vitro and also significantly delayed growth of mouse tumor xenografts in vivo. Simeprevir caused prolongation of γH2AX foci after irradiation, decreased invasion / migration and downregulation of PD-L1 expression.
Conclusion:
Targeting PI4K IIIα using anti-HCV agent could be a viable drug repositioning approach to enhance the therapeutic efficacy of radiotherapy for breast cancer, Material and Methods: Syngeneic Lewis lung carcinomas were grown either orthotopically or subcutaneously in C57BL/6 mice and were irradiated with a single dose of 15 Gy to mimic SABR used in the clinic. Serial [18F]-misonidazole (F-MISO) positron emission tomography (PET) imaging, pimonidazole FACS analyses, hypoxia-responsive element (HRE)-driven bioluminescence, and Hoechst 33342 perfusion were performed before irradiation (d-1), at 6 hours (d0), 2 (d2), and 6 days (d6) after irradiation for both subcutaneous and orthotopic lung tumors. For F-MISO, scan was performed 2 hr after the intravenous injection of F-MISO probe and the tumor-to-brain ratio (TBR) was analyzed.
Results:
We observed that hypoxic signals were too low to quantitate for orthotopic tumors by F-MISO PET or HRE-driven bioluminescence imaging. In subcutaneous tumors TBR values were 2.87 ± 0.483 at d-1, 1.67 ± 0.116 at d0, 2.92 ± 0.334 at d2, and 2.13 ± 0.385 at d6, indicating that tumor hypoxia was decreased immediately after irradiation and returned to the pretreatment levels at d2, followed by a slight decrease by d6 post-radiation. Pimonidazole analysis also revealed similar patterns. By using Hoechst 33342 vascular perfusion dye and CD31 co-immunostaining, we found that there was a rapid and transient vascular collapse, which may have resulted in poor intratumoral perfusion of F-MISO PET tracer or pimonidazole delivered at d0 leading to decreased hypoxic signals at d0 by PET or pimonidazole analyses. 
Conclusion:
We found tumor hypoxia levels to be returned to the pretreatment levels by 2 days after irradiation, hence supporting the current fractionation intervals of SABR being given at least 2 days. Our results also indicate that SABR may produce a rapid but reversible vascular collapse in tumors.
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